Treatment
Tislelizumab clinical trials
We’re tracking 219 recruiting studies that include Tislelizumab, each written for real people, not researchers, below.
Recruiting studies
- NCT06364956RecruitingPhase 1/Phase 2
Testing new drug combo for bladder cancer before surgery
This trial tests a combination of two drugs (Tislelizumab and Palbociclib) given before bladder removal surgery. It is for people with bladder cancer that has a specific genetic change and who cannot take the standard chemotherapy cisplatin.
Guangzhou, GuangdongAges 18 years+ - NCT06499350RecruitingPhase 1/Phase 2
New combo for advanced solid tumors after standard therapy
This trial tests a new combination of drugs (FC084CSA plus tislelizumab) for people with advanced solid tumors, especially lung cancer that has gotten worse after prior immunotherapy and chemotherapy. It may be an option if you've tried standard treatments and they no longer work.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06167785RecruitingPhase 2
Study of zanubrutinib and tislelizumab for lymphoma after CAR-T
This trial tests two new drugs (zanubrutinib and tislelizumab) for people with large B-cell lymphoma that has come back or not responded after CAR-T therapy. The goal is to see if these drugs can help when CAR-T hasn't worked.
Toronto, OntarioAges 18 years+ - NCT05595590RecruitingPhase 2
Radiation plus immunotherapy for recurrent head and neck cancer
This study tests whether adding an immunotherapy medicine called tislelizumab to radiation can better control recurrent (coming back) head and neck squamous cell cancer. It is aimed at people whose cancer can’t be fully removed by surgery or can’t be safely removed.
Chengdu, SichuanAges 18–75 - NCT05536102RecruitingPhase 2
Surgery-plus chemo and immunotherapy for HER2-negative gastric cancer
This Phase 2 trial studies whether adding two medicines (XELOX and tislelizumab) and another chemotherapy drug (PLD) around the time of surgery works better and is safe for people with stage III gastric (stomach) cancer. It is designed for tumors that are HER2-negative and PD-1/L1 positive.
ShanghaiAges 18–75 - NCT05286957RecruitingPhase 2
MRD-guided immunotherapy plus chemo after lung cancer surgery
This trial tests whether adding a cancer-fighting immunotherapy (tislelizumab) and chemotherapy after surgery can lower the chance of lung cancer coming back. It uses “MRD” (measurable remaining disease) to help decide who may benefit the most after resection.
Zhengzhou, HenanAges 18–80 - NCT05687357RecruitingPhase 2
Tislelizumab plus chemoradiation before surgery for stomach cancer
This Phase 2 trial studies giving tislelizumab (an immune therapy) together with pre-surgery chemoradiation for locally advanced stomach or GEJ (esophagus-stomach junction) adenocarcinoma. It compares this approach to the standard treatment (chemoradiation plus surgery) to see if it improves outcomes.
Wuhan, HubeiAges 18–75 - NCT05917431RecruitingPhase 2
Radiation plus immunotherapy and targeted pills for liver cancer
This Phase 2 trial studies whether a combination of SBRT (focused radiation) plus tislelizumab and regorafenib can control unresectable or limited-spread liver cancer. It may help by attacking tumors in the liver and immune system to improve shrinkage and control of disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05862168RecruitingPhase 2
Tislelizumab with chemotherapy before surgery for oral cancer
This trial studies giving tislelizumab (an immune treatment) plus chemotherapy before surgery to shrink and treat locally advanced oral squamous cell cancer. It aims to improve tumor response and outcomes, while checking safety.
HangzhouAges 18–75 - NCT05954897RecruitingPhase 2
Lenvatinib plus tislelizumab with HAIC for advanced liver cancer
This Phase 2 study tests whether combining three treatments—lenvatinib, tislelizumab, and a liver-directed chemotherapy approach (HAIC)—can shrink advanced hepatocellular carcinoma. It may help people whose cancer is stage C and hasn’t been treated before.
Guangzhou, GuangdongAges 18 years+ - NCT05984342RecruitingPhase 1
Tislelizumab plus chemo after surgery for lymph node-positive esophageal cancer
This trial tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy after surgery can help prevent esophageal cancer from coming back. It is for people whose cancer had spread to lymph nodes at the time of surgery.
Shantou, GuangdongAges 18–70 - NCT05511623RecruitingPhase 2
Tislelizumab with chemoradiotherapy for stage IIIC2 cervical cancer
This trial tests whether adding tislelizumab to standard chemotherapy and radiation works better as first treatment for stage IIIC2 cervical cancer. It aims to improve how well the cancer responds and controls the disease.
Nanning, GuangxiAges 18–70 - NCT06056115Recruiting
Tislelizumab for lung cancer with brain metastases
This trial tests a drug called tislelizumab for people with advanced lung adenocarcinoma that has spread to the brain but is not causing symptoms. It is for those who have not had prior treatment and whose tumors do not have certain gene changes.
Shijiazhuang, HebeiAges 18–75 - NCT06056336RecruitingPhase 2
Perioperative tislelizumab plus chemo for esophageal cancer
This trial tests whether giving tislelizumab (an immunotherapy) along with chemotherapy before and after surgery can help people with a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this combination improves outcomes for patients whose cancer is in the chest and can be removed with surgery.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05360277RecruitingPhase 2
Maintenance immunotherapy and chemo after surgery for metastatic colon cancer
This Phase 2 trial studies tislelizumab plus capecitabine given after surgery to help prevent metastatic colorectal cancer from coming back. It may be an option if you recently had surgery that removed visible disease and you have good overall health.
Guangzhou, GuangdongAges 18–80 - NCT05604560RecruitingPhase 2
New drug combo before surgery for resectable pancreatic cancer
This trial tests two drugs, tislelizumab and SX-682, given before surgery for people with pancreatic cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
Baltimore, MarylandAges 18 years+ - NCT05515315RecruitingPhase 2
Immunotherapy plus chemo then chemoradiation for esophageal cancer
This Phase 2 study tests whether adding tislelizumab (an immunotherapy drug) to chemotherapy before a combined course of chemotherapy and radiation can better treat locally advanced, non-surgable esophageal squamous cell cancer. It’s for adults who cannot have surgery and may help shrink the cancer and improve control of the disease.
Fuzhou, FujianAges 18–70 - NCT06254521RecruitingPhase 2
Tislelizumab plus chemo before surgery for MSS rectal cancer
This trial tests a combination of an immunotherapy drug (tislelizumab) plus chemotherapy before surgery for people with a specific type of rectal cancer that has not spread to other organs. The goal is to see if this approach can shrink the tumor more effectively than standard treatment.
Nanning, GuangxiAges 18 years+ - NCT05477264RecruitingPhase 2
Tislelizumab with radiation for early nasal lymphoma
This trial tests whether adding a medicine called tislelizumab to radiation works better than radiation alone for newly diagnosed nasal (nasal-type) NK/T-cell lymphoma. If you qualify, it may help control the cancer and improve outcomes by using both treatments together.
SeoulAges 19 years+ - NCT05699655RecruitingPhase 2/Phase 3
New pre-surgery treatment for advanced stomach cancer with immunotherapy
This trial tests a new combination (tislelizumab plus apatinib and chemotherapy) before surgery for certain advanced stomach cancers, compared with the standard chemotherapy plus S1. The goal is to shrink the tumor and improve outcomes before and around surgery.
Fuzhou, FujianAges 18–75 - NCT07811752RecruitingPhase 2
Combination treatment for advanced esophageal cancer
This trial tests a combination of two drugs for advanced esophageal cancer that has grown despite earlier treatment. The goal is to see if this combination can help shrink tumors and slow the disease.
ShanghaiAges 18 years+ - NCT07815223RecruitingPhase 2
Immunotherapy and targeted drug after chemoradiation for limited-stage small cell lung cancer
This trial tests whether adding two medications—tislelizumab (an immunotherapy that helps your immune system fight cancer) and anlotinib (a targeted drug that blocks blood supply to tumors)—after standard chemoradiation can help keep limited-stage small cell lung cancer from coming back. It may offer a new option to improve outcomes for patients who have already responded to initial treatment.
Yantai, ShandongAges 18–75 - NCT06560528RecruitingPhase 2
Drug combo before & after surgery for HER2+ stomach cancer
This trial tests a combination of three drugs (targeted therapy, immunotherapy, and chemotherapy) before and after surgery for locally advanced HER2-positive stomach cancer. It aims to see if this treatment can improve outcomes for patients whose cancer has not yet spread.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07733180RecruitingPhase 2
Study of tislelizumab plus chemo for advanced esophageal cancer
This trial tests different schedules of tislelizumab (an immunotherapy drug) combined with chemotherapy for Japanese patients with advanced esophageal squamous cell carcinoma that cannot be removed by surgery or has spread. It aims to find a better way to give these treatments together.
Yokohama, KanagawaAges 18 years+
Common questions
- Are there clinical trials studying Tislelizumab?
- Yes. Clin2 currently lists 219 recruiting studies that include Tislelizumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Tislelizumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Tislelizumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Tislelizumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.